BRCA2 and breast carcinoma: Indeed, HGSOC with diminished BRCA1 or BRCA2 expression typically have increased sensitivity to DNA damaging chemotherapeutics and restoration of BRCA1 in a BRCA1 deficient breast cancer cell line decreased cisplatin sensitivity in a xenograph model [38, 39].